Press "Enter" to skip to content

Eli Lilly blows past estimates, hikes sales outlook on resilient Zepbound and Mounjaro demand

https://news.google.com/rss/articles/CBMidkFVX3lxTE9NdFQ3UUxsNVQtQmtLandjang0Nk5QZ2xEb3B1TU11X2dYVUdVSUFNaTdLOGhCR3VTUVdlT19WY0VkVE1FMm9uUzhIckpsT1BmM1RVbUw1ZWJZVTJ3MVdxREZlVVlPRXZjTjMzTXoxWXhMaVpEQUHSAXtBVV95cUxOOU9NT0xZb0dQZ3g4a19zaThfLWltR1N6OFJzQjVxOXVNeDRZWnhNQnRqWHMybTZDODQ1b3pPVXRRT18zYVZBUHBiN3dUN1RYQXoyQ3AtWkZkXzRWSWl1NVppWFR0YndnNF9sNXJxdzlHdVVlLWlfclBJRkU?oc=5
Eli Lilly blows past estimates, hikes sales outlook on resilient Zepbound and Mounjaro demand  CNBCLilly reports third-quarter 2026 financial results, raises full-year guidance and highlights regulatory progress across the portfolio  Eli LillyEli Lilly (NYSE:LLY) reports upbeat Q3 2026, guides for strong full-year sales  Yahoo FinanceLilly Raises Sales Guidance…

More from UncategorizedMore posts in Uncategorized »